As part of the plan, Amazon has agreed to purchase 100,000 electric delivery vans from vehicle manufacturer Rivian.Technologyread more
At least in terms of monetary policy, Pence says should be taking after other regions who keep their benchmark interest rates near zero.Delivering Alpharead more
The plan will allow Medicare to negotiate lower prices on as many as 250 drugs and apply those discounts to private health plans.Health and Scienceread more
Hedge fund titan Leon Cooperman said he's concerned about a shift to the left in the political landscape, which could harm the economy and the stock market.Delivering Alpharead more
Apple's big iOS 13 update for iPhones is out now and includes lots of new features. Here's how to install it on your phone and what devices are supported.Technologyread more
The pilot program will deliver food and beverage, over-the-counter medications and other items within minutes, the company said. Prescription deliveries will not be available.Health and Scienceread more
The FDA's Office of Criminal Investigations opened a probe "shortly after" people started falling ill, Mitch Zeller, director of the FDA's Center for Tobacco Products, told...Health and Scienceread more
Investor Jim Chanos is betting against GrubHub, and said the food delivery company makes almost nothing per order.Delivering Alpharead more
Billionaire investor Leon Cooperman on Thursday said he believes that the Federal Reserve is "screwing the savers."Delivering Alpharead more
Datadog priced its stock at $27, selling 24 million shares and raising $648 million in its IPO.Technologyread more
"We sell the most mission-critical identity security to the largest global enterprises around the world," says Ping Identity CEO Andre Durand.Marketsread more
Biogen's offer of $25.50 per share, represents a premium of 68 percent to Nightstar's Friday close of $15.16.
Gene therapy, an emerging field of biotechnology, uses specially engineered viruses, or viral vectors, to deliver genetic material into defective cells, in hopes of improving or potentially even curing an inherited condition.
London-based gene therapy company Nightstar is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders.
"Ophthalmology is an emerging growth area for Biogen," said Michel Vounatsos, Biogen's chief executive officer. "Nightstar would accelerate our entry into ophthalmology by contributing two mid- to late-stage gene therapy assets."
Biogen said it plans to fund the acquisition through available cash.
Last week, Sarepta Therapeutics Inc beefed up its gene therapy portfolio through the purchase of its partner Myonexus Therapeutics, while Swiss drugmaker Roche said it was buying U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion.
Goldman, Sachs is acting as financial adviser to Biogen and Centerview Partners was Nightstar's financial adviser.